



Modern Tools to Meet the Challenges of Preclinical Translation to the Clinic

Maximizing GSP and Emerging Technologies

Steven Novick, Senior Director
Head of Nonclinical Statistics, Takeda

June, 2025

Better Health, Brighter Future



Admission and Acknowledgments



I don't work on many projects anymore...

Thanks to these members from the Takeda preclinical stats team:

- Pietro Artoni
- Reuben Retnam
- Yue Yang

...I also asked ChatGPT

Pharmaceutical Companies make drugs!



Discovering Drugs is a difficult task



90% of clinical drugs fail (Sun et al, 2022)

➡➡➡➡ The process of drug discovery ➡➡➡➡

Target
identification

Target
validation

Pre-clinical
dev.

Clinical
dev.

Long journey

Target ID (TI)

Target validation (TV)


Hit ID (HI)

Lead Optimization (LO)




2010s: Lack of replicable results motivated GSP

Baker et al 2016 Nature



- 70% failed to replicate another scientists experiments
- 50% failed to replicate their own experiments

Findings confirmed in only 14 out of 67 studies (21%)



Prinz F, Schlange T, Asadullah K (2011). *Nat Rev Drug Discov* 10(9): 712.

Findings confirmed in only 6 out of 53 studies (11%)

COMMENT

Raise standards for preclinical cancer research


Glenn Begley and Lee M. Ellis propose how methods, publications and incentives must change if patients are to benefit.

Abstract: The high cost of drug development and the low success rate in bringing new drugs to market have led to a crisis in the pharmaceutical industry. The authors argue that this is due to a lack of transparency in the publication of research results, particularly in the pharmaceutical industry, where the focus is often on the positive results of a project, rather than the full range of outcomes. This leads to a biased view of the success of a project, and a lack of understanding of the challenges involved in drug development. The authors call for a more open and transparent approach to research, where all results are published, and the full range of outcomes is shared. This would allow researchers to learn from their mistakes, and to build on the successes of others. It would also allow the public to see the full picture of the research process, and to understand the challenges involved in bringing a new drug to market. The authors argue that this is essential for the future of drug development, and for the health of the world.

Table of Contents:

- Introduction
- The challenges of drug development
- The need for better standards in preclinical research
- Proposed changes to methods, publications and incentives
- Conclusion

Begley CG, Ellis LM (2012). Drug development: *Nature* 483(7391): 531-533.



- ➔ Interpretable results
- ➔ Reproducible
- ➔ Confidence in findings

We operate under
The Scientific Method



Good statistical Practice (GSP) adds
statistical rigor and confidence to
the scientific method

Preece, D. A. “**Good Statistical Practice.**” *Journal of the Royal Statistical Society. Series D (The Statistician)*, vol. 36, no. 4, 1987, pp. 397–408. JSTOR, <https://doi.org/10.2307/2348838>.

Reynolds PS. Between two stools: preclinical research, reproducibility, and statistical design of experiments. *BMC Res Notes*. 2022 Feb 21;15(1):73. doi: 10.1186/s13104-022-05965-w. PMID: 35189946; PMCID: PMC8862533.

Percie du Sert, N., Hurst, V., Ahluwalia, A. *et al.* **The ARRIVE guidelines 2.0:** Updated guidelines for reporting animal research. *BMC Vet Res* **16**, 242 (2020). <https://doi.org/10.1186/s12917-020-02451-y>

Good Statistical Practice

Study Design

Statistical
Analysis Plan
(SAP)

Reproducibility
Interpretability
(R&I)

Efficiency

Confidence

R&I

THE
SCIENTIFIC
METHOD

Result

Observation

Question

Hypothesis


Experiment

Conclusion



Good Statistical Practice

Purpose of Study	✓
Outcome Measurements + signal window	✓
Success criteria	✓
Controls/comparators	.
Experimental design	.
Estimation/testing strategy	.
Decision criteria	.
Sample size justification	.
Randomization into groups	.
Sample processing order	✓
Blinding	✓
Monitoring	✓



ARRIVE guidelines

The ARRIVE guidelines (Animal Research: Reporting of *In Vivo* Experiments) are a checklist of recommendations for the full and transparent reporting of research involving animals – maximising the quality and reliability of published research, and enabling others to better scrutinise, evaluate and reproduce it.

ARRIVE guidelines >

The ARRIVE guidelines
embody GSP



GSP Alone is Not Enough



Remember:

90% of clinical drugs fail (Sun et al, 2022)

The root issues:

- *Poor reproducibility*
- *Statistical inefficiencies*
- ***Misalignment of preclinical models with human biology***



IMED Biotech Unit
2017 – A year in review



AstraZeneca's 5Rs

Right Target

Right Tissue

Right Safety


Right Patient

Right Commercial

Find the right target




Difficult before 2008...




Genetic Information
Nondiscrimination Act of 2008

President George W. Bush signs H.R. 493, the Genetic Information Nondiscrimination Act of 2008, Wednesday, May 21, 2008, in the Oval Office. White House photo by Eric Draper.


Omics, pre-2008



Modern omics



Timeline of gene-expression assays



Martinez-Perez et al (2022)


Patients reluctant to provide genetic data

2008

Citizens pay for analysis of DNA

Ancestry DNA
My Heritage
Etc.

Public databases of gene-expression data





Types of omics data

- Genomics
- Epigenomics
- Phenomics
- Glycome
- Single-cell RNA sequencing
- Proteomics
- Metabolomics
- DNA reference sequences
- Lipidome
- Transcriptomics
- Metagenomics
- Pharmacogenomics
- RNA sequencing

List pulled from Google search, 27-April-2025

Data integration, Multiomics



Chen et al (2020). "Applications of multi-omics analysis in human diseases." MedComm

Traditional 'omics analyses are [now] more meaningful



1. Differential Expression Analysis

2. Pathway Enrichment Analysis

In many cases, we collect selective panels of gene/protein expression data

3. Network Analysis

4. Genome-Wide Association Studies (GWAS)

Given benchmarks against human results,

➔ more confidence in novel findings

Reverse Translated Biomarkers for Enhanced Translation



Alzheimer's Disease

- Clinical studies show accumulation of amyloid-beta plaques in human brain

Led to development of mouse model


- Mimics amyloid-beta pathology (e.g., 5xFAD, APP/PS1 transgenics)

Human

Mouse: 5xFAD

<https://radiology.ucsf.edu/patient-care/services/specialty-imaging/alzheimer>

Damuka N, Irmen RE, Krizan I, Miller M, Gollapelli KK, Bhoopal B, Deep O, Bansode A, Lockhart SN, Orr ME, Jadiya P, Bashetti N, Kumar JVS, Mintz A, Whitlow CT, Craft S, Macauley SL, Solingapuram Sai KK. Exploring microtubule dynamics in Alzheimer's disease: Longitudinal assessment using [^{11}C]MPC-6827 PET imaging in rodent models of Alzheimer's-related pathology. *Alzheimers Dement*. 2024 Sep;20(9):6082-6093. doi: 10.1002/alz.14083. Epub 2024 Jul 5. PMID: 38967283; PMCID: PMC11497705.



Psoriasis (chronic autoimmune skin disease)

- Clinical studies found IL-17A and IL-23 cytokines highly elevated in psoriatic skin and blood
- Correlation with disease severity (PASI score — Psoriasis Area and Severity Index)

Led to development of mouse model to drive IL-17A/IL-23 activation

Mimics human psoriasis →

Li, Q., Liu, W., Gao, S. *et al.* Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist. *BMC Immunol* **22**, 11 (2021).
<https://doi.org/10.1186/s12865-021-00401-3>



IL-17A Antibody on C57BL/6 Mice

Deciding on the right target



Multiparameter Optimization (MPO)




Decision theory technique to simultaneously optimize a set of factors against an objective

Rank order alternatives

	Alternative			Criterion Weights
	1	2	3	
Efficacy	##	##	##	##
Safety	##	##	##	##
Quality of Life	##	##	##	##
Functional Status	##	##	##	##
Dosing Convenience	##	##	##	##
Price	##	##	##	##
Cost-Effectiveness	##	##	##	##
Budget Impact	##	##	##	##


Harrington, E.C. (**1965**) The Desirability Function. Industrial Quality Control, 21, 494-498.

Each feature is matched with a desirability function



Desirability: $0 < d < 1$

Subjectively chosen



Infinite variety of desirability functions


Source: https://cran.r-project.org/web/packages/desiR/vignettes/Gene_ranking.pdf

Overall desirability



	Value					desirability				
Target	Log2 FC gene1	Log2 FC gene2	Corr	# Articles	Market (\$B)	Log2 FC gene1	Log2 FC gene2	Corr	# Articles	Market
						2x	1x	1x	0.5x	0.25x
A	0.617	1.116	0.410	0	7	0.48	0.59	0.41	0.20	1.00
B	1.199	-0.871	0.357	1	2	0.96	0.10	0.36	0.40	0.29
C	0.015	1.500	0.579	3	7	0.10	0.77	0.58	0.80	1.00
D	0.699	0.074	0.883	1	1	0.62	0.13	0.88	0.40	0.14
E	1.864	0.633	0.806	4	5	1.00	0.31	0.81	1.00	0.71
F	0.208	0.964	0.437	0	7	0.10	0.50	0.44	0.20	1.00
G	0.850	1.137	0.478	3	7	0.81	0.61	0.48	0.80	1.00
H	0.041	2.315	0.375	1	6	0.10	0.94	0.38	0.40	0.86

Overall D = weighted geometric mean



Target	Desirability
E, G	0.6 – 1 [Top choices]
A, B, D	0.4 – 0.6 [Grey area]
C, F, H	0 – 0.4 [Avoid these]

Subjective, but still great



MPO significantly enhances decision-making in preclinical drug development

- Integrates expert knowledge, study data
- Evaluates trade offs among multiple targets or attributes
- Further refinement steps, such as compound diversity analyses and LLM-augmented summaries of evidence



Machine Learning and AI



Photo is of Secretary of Education,
Linda McMahon at Educators
Convention in San Diego, April 8,
2025


Knowledge Graphs (KG)




- Links explicit knowledge with inferred relationships
- Genes/proteins/disease are nodes
- Relationships are edges

By analyzing connections, KGs can uncover hidden or non-obvious relationships, identifying potential targets

+ predictive analytics can suggest new drug-target connections or repurpose existing drugs



Find the right tissue




Analysis of single cell RNAseq

- Classifiers to determine cell types
- Spatial Tx

Fewer false pos/neg in
DEG associated with cell types

Avey et al (2018). "Single-Cell RNA-Seq Uncovers a Robust Transcriptional Response to Morphine by Glia." Cell Rep.

Single cell proteomics




Goto-Silva L, Junqueira M. Single-cell proteomics: A treasure trove in neurobiology. *Biochim Biophys Acta Proteins Proteom.* 2021 Jul;1869(7):140658. doi: 10.1016/j.bbapap.2021.140658. Epub 2021 Apr 12. PMID: 33845200.

Given the right target and tissue...



Digital Hit Screening




Cell Painting for hit screening, drug repurposing

Provides profile cellular phenotypes that dye organelles or cellular components.

Microscopy + image analysis
Differentiate cellular morphology

Gally et al (2020)
Identifying bioactivity of pseudo-natural products using the Cell Painting assay

Organs on a chip




Traditional 2D cell cultures often fail to capture human-disease biology effectively. Enter 3D-organoid cultures and organs-on-chip platforms, which have brought us closer to mimicking human tissue functionality




Predict side effects and human toxicity and associated mechanisms

Modern translation



Digital biomarkers







EEG data for Parkinson's,
epilepsy

Lainscsek et al (2013)


Non-Linear Dynamical Analysis of EEG Time Series Distinguishes
Patients with Parkinson's Disease from Healthy Individuals



Zhang, et al (2018)
A wearable system for olfactory electrophysiological recording and animal motion control

Chen et al (2020)
Wireless AI-Powered IoT Sensors for Laboratory Mice Behavior Recognition

Enhanced Translation: Behavioral Phenotyping



AI driven models of physiological and behavioral signals

Preclinical

Quadruped gait

Ultrasonic Vocalizations

Temperature monitoring

Core behaviors

Clinical

Biped gait

Speech biomarkers

Temperature monitoring

Quality of life

- Translating *video* motor phenotyping of behavioral information
- Provides quantitative measurements of gait and complex behaviors in home cage



Grooming



Eating



Walking



Rearing



Drinking

Leveraging AI tools on
AWS Insight:

- deeplabcut (tracking)
- b-soid (ethology)

Feature extraction &
statistical modeling

Neurodegenerative diseases




T Tremor: shaking, usually starting on one side

R Rigidity: stiffness of the limbs, neck, or trunk

A Akinesia: loss or impairment in power of voluntary movement

P Posture and balance




Reverse translation

Inflammation Model



Ear scratching



Key Takeaways



- Statistical rigor is essential via GSP
- GSP alone is insufficient to sustain a successful preclinical pipeline
- Sets of tools that take advantage of troves of data
- Knowledge Graph, LLM, or generative AI
- New Approach Methodologies (NAMs): Organs on a chip
- Reverse translation

THANK YOU!



Better Health, Brighter Future

© 2021 Takeda Pharmaceutical Company Limited. All rights reserved